In this article, Andrew Butcher writes about the importance of stakeholder engagement as effective but high-cost new therapies have potentially damaging financial implications for the healthcare systems expected to fund them. Regrettably, the pharmaceutical industry is often identified as the cause of the problems rather than the key players in solving them.
Life sciences considerations for investment treaty disputes
Greg Bell, Andrew Tepperman, and Justin Ho co-authored a chapter in the ninth edition of The Investment Treaty Arbitration Review. The chapter titled...